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Cancer prevalence in 129 breast-ovarian cancer families 
tested for BRCA1 and BRCA2 mutations
C M Schlebusch, G Dreyer, M D Sluiter, T M Yawitch, H J van den Berg, E J van Rensburg 
Breast cancer is the most common malignancy among women 
in South Africa, with a crude incidence rate of 18.5/100 000 
recorded between 1993 and 1995.1 A small but significant 
percentage (5 - 10%) of breast cancer cases are directly due 
to an inherited susceptibility.2 Two tumour suppressor genes 
involved in early-onset breast and ovarian cancer, BRCA1 and 
BRCA2, have been mapped and cloned.3,4 These two genes 
explain 20 - 40% of heritable breast cancer cases in various 
populations over the world.5,6 A large linkage and mutation 
study on 237 families collected by the Breast Cancer Linkage 
Consortium found that overall BRCA1 accounts for 52% of all 
families, and BRCA2 for 32%, leaving 16% of the families with 
a familial breast cancer phenotype unaccounted for.7 In the 
study, 81% of the families with both a breast and an ovarian 
phenotype were BRCA1-positive families while 14% linked to 
BRCA2. The situation was reversed in families that presented 
with a male breast cancer phenotype in addition to female 
breast cancer, where 76% linked to BRCA2 and only a small 
percentage to BRCA1.
Worldwide many families with a strong history of familial 
breast cancer have been fully screened for BRCA1 and BRCA2 
mutations but none were found. This is especially the case in 
breast cancer-specific families (no other cancers beside breast 
cancer in family). While the search for the BRCA1 and BRCA2 
genes was helped by the strong association of ovarian cancer in 
addition to breast cancer with BRCA1 and male breast cancer 
with BRCA2, the search for other breast cancer-associated genes 
is more complicated. Studies on BRCA1- and 2-negative breast 
cancer families showed that the most probable explanation is 
that there are multiple additional genes with lower penetrance 
and/or prevalence, each responsible for a small number of 
families.8,9
The functions of the BRCA genes have not been fully 
elucidated, but they are broadly classified as tumour 
suppressor genes with functions in DNA repair and 
recombination, cell cycle regulation through checkpoint control 
and transcription regulation.10,11 Owing to their function in 
cell cycle regulation and damage response, mutations in these 
genes are expected to lead to susceptibility for deregulation 
and cancer in more than one tissue type. It is unclear 
why mutations in these two genes are mainly involved in 
malignancies in the breast and ovaries, but it is thought that 
some interaction with the female hormones, oestrogen and 
progesterone, may be responsible.12
Mutations within BRCA1 and BRCA2 have been 
demonstrated to contribute to an increased risk of cancers 
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Background. Women who carry germline mutations in the 
breast-ovarian cancer susceptibility genes, BRCA1 and 
BRCA2, are at very high risk of developing breast and/or 
ovarian cancer. Both genes are tumour suppressor genes 
that protect all cells from deregulation, and there are reports 
of their involvement in other cancers that vary and seem 
to depend on the population investigated. It is therefore 
important to investigate the other associated cancers in 
different populations to assist with risk assessments. 
Objectives. To assess the cancer risk profile in BRCA-mutation-
positive and negative South African breast-ovarian cancer 
families, mainly of Caucasian origin. 
Design. Descriptive study in which the prevalence of all 
cancers in the pedigrees of BRCA1- and BRCA2-mutation-
positive groups and a group of families without mutations in 
either gene were compared with the general population. 
Results. As expected, female breast and ovarian cancer was 
significantly increased in all three groups. Furthermore, male 
breast cancer was significantly elevated in the BRCA2-positive 
and BRCA-negative groups. Stomach cancer prevalence 
was significantly elevated in the BRCA2-positive families 
compared with the general population. 
Conclusions. These results can be applied in estimation of 
cancer risks and may contribute to more comprehensive 
counselling of mutation-positive Caucasian breast and/or 
ovarian cancer families.
S Afr Med J 2010; 100: 113-117.
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other than breast and ovarian cancer. Friedenson summarised 
32 studies (involving >70 000 individuals) that investigated 
the elevated risks for other cancers, associated with these 
two genes.13 The increased risks range from 20% to 60%, 
with the most important increases in cancers of the stomach 
and pancreas. BRCA2 confers an elevated risk to a broader 
spectrum of cancers than BRCA1. Many reviewed studies, 
however, had conflicting reports, stressing the importance of 
contributing genetic factors and environmental influences that 
may differ between populations. 
We studied the occurrence of different types of cancer in 
127 Caucasian and 2 non-Caucasian South African families 
with a positive breast cancer history. Complete mutation 
analysis allowed division of these families into BRCA1-
mutation positive, BRCA2-mutation positive and families 
with no mutation in either gene. The pedigrees of these three 
groups of families were compared to determine the respective 
contribution of BRCA1 and BRCA2 to breast and ovarian cancer 
and to establish which other cancers may be associated with 
mutations in these genes.
The study was approved by the Ethics Committee of the 
University of Pretoria (Protocol 18/98).
Methods
Selection of patients
Participating families were obtained through a familial 
cancer clinic at the University of Pretoria. Families willing 
to participate and with a family history (3 or more cases 
with breast and/or ovarian cancer) suggestive of inherited 
susceptibility were included. 
We assembled a total of 129 (127 Caucasian and 2 non-
Caucasian) families: 81/129 (62.8%) were Afrikaners, mainly 
descended from Dutch, German and French immigrants to the 
South African Cape during the early 17th century,14 Ashkenazi 
Jewish families represented 15.5 % (20/129), 12.4% (16/129) 
were of British/UK origin, and 2.32% (3/129) were of Dutch 
descent.  In addition, there were single families of Afrikaner-
Lebanese, Austrian, Belgian, German, German-British, Polish 
and Portuguese descent. The 2 non-Caucasian families were a 
black South African and a South African Indian family.
A blood sample from index individuals (affected with breast 
and/or ovarian cancer) in these families was obtained with 
informed consent, and the two BRCA genes were screened for 
mutations using single-strand conformation polymorphism 
and heteroduplex analysis (SSCP/HA), protein truncation test 
(PTT) and multiplex ligation-dependent probe amplification 
(MLPA) methods. Of the 129 families, 26 tested positive for a 
mutation in BRCA1 and 43 for a mutation in BRCA2, while 60 
remained unassigned (‘BRCA negative’) after full screening.15,16 
The three groups were analysed to determine the prevalence of 
cancer in family members.
Pedigree analysis
Information regarding cancer cases in the families were 
obtained from the index individuals and were not verified 
with pathological reports. The reliability of the information, 
especially for more distant relatives, may be lower than that 
for first- and second-degree relatives’ cancers. Females and 
males included in the analysis were only from the branches of 
the pedigree (paternal or maternal) that were believed to carry 
mutations in one of the BRCA genes. Only the index cases were 
screened for mutations; none of the other family members in 
the pedigree were screened. The assumptions of the inheritance 
of the mutation were based primarily on the occurrence of 
breast and ovarian cancer in females and secondarily on other 
cancers in all individuals. Where there were cancers in both 
branches of the family, the branch with the most cancers in the 
closest relatives were included. For the previous generations, 
all males and females in the pedigrees were included, up to the 
generation where the first reported case appeared. Persons in 
more current generations were included only if they were born 
before 1960 (~40 years old at time of analysis). This therefore 
excludes very young persons who would not yet have 
developed cancer. 
The number of females in the pedigrees was used in 
calculations for female-specific cancers, and the same applies 
for the male-specific cancers. In the case of cancer affecting 
both the female and male populations the unknown gender 
counts were included. Bilateral cases (in females and males) 
were counted as two separate cases, but only the age at first 
diagnosis was used in calculations regarding age. 
For the chi-square test the expected number of cancer cases 
was obtained by multiplying the population risk with the 
total number of individuals in the group. The population risk 
in South African individuals for 1993 - 1995 was obtained 
from the National Cancer Registry (NCR).1 The Cancer 
Registry data are limited in that they only supply information 
on histopathologically confirmed tumour data and not on 
population-based data. These data are at best a minimal 
estimate of ‘population’ risks. Cancer risks in the Caucasian 
population of South Africa were used for the calculations, since 
the majority of the study families were of Caucasian origin 
(only 2 families were non-Caucasian, i.e. 1 black in the BRCA-
negative group and 1 Indian in the BRCA1-positive group). For 
the chi-square tests for cancers, which are not gender specific, 
the mean between the cancer risk of Caucasian males and 
females in South Africa was used.  
Results 
Mutation-positive families constituted 53% of the total families. 
The BRCA2-positive families were largely site-specific breast 
cancer families (33/43), compared with the BRCA1-positive 
families (6/26) (Table I). The total number of individuals in 
all the pedigrees included was 3 682 with an average of 28.5 
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individuals per pedigree. The gender of 97% was known, with 
57% being female. The total number of all cancer cases per 
pedigree was higher in the BRCA-positive groups than in the 
BRCA-negative group (Table I). The prevalence of breast cancer 
was high in all three groups, with the highest prevalence in 
the BRCA2-positive group (Table I). Bilateral breast cancer was 
more common in both the mutation-positive groups. Ovarian 
cancer occurred mostly in the BRCA1-positive group, with the 
BRCA2-positive and mutation-negative groups comparable 
(Table I). Male breast cancer and cancers other than breast and 
ovarian cancer were most prevalent in the BRCA2-positive 
group.
Table II compares the observed cancers in the study groups 
with the expected number of cancers (based on NCR data on 
the general Caucasian population risk1). The results concerning 
cancers typically associated with the two BRCA genes, namely 
breast and ovarian cancer for BRCA1 and breast, ovarian and 
male breast cancer for BRCA2, were anticipated. The observed 
prevalence of these cancers compared with the expected 
prevalence based on the general Caucasian population risk 
was also elevated in the mutation-negative group. This is to be 
expected, as the criterion on which families were selected was 
that they must have at least three breast and/or ovarian cancer 
cases. These families would therefore by default have a higher 
than expected prevalence of breast and ovarian cancer.
Male breast cancer had a higher prevalence than expected in 
the BRCA2-positive (p<0.00001) and BRCA-negative (p=0.0022) 
groups, but not in the BRCA1-positive group (Table II). The 
only other cancer with a significantly increased prevalence 
(p=0.0001) was stomach cancer in the BRCA2-positive group. In 
all three groups prostate, colon, bladder and lung cancers and 
melanoma had a significantly lower prevalence than expected. 
Overall, the prevalence of cancers in total was higher in all 
three study groups (p<0.00001) compared with what would be 
expected from the general Caucasian population data (Table II).
Discussion
Breast cancer
Breast cancer prevalences for the BRCA1-positive group and 
the BRCA-negative group were similar (p=0.843) (Table I). The 
BRCA2-positive group had a significantly higher prevalence of 
breast cancer than the BRCA1-positive group (p=0.015) and the 
BRCA-negative group (p=0.009), which seems to indicate that 
a higher breast cancer risk is associated with BRCA2 than with 
BRCA1 (Table I). Generally BRCA2 mutation penetrance for 
lifetime risk of breast cancer is lower than for BRCA1 mutation 
carriers, resulting in a later age of onset.13 This was also 
apparent in our study, where more BRCA1-positive individuals 
than BRCA2-positive individuals were diagnosed with breast 
cancer below the age of 50 years (Table I).
Ovarian cancer
Previously the cumulative risk for ovarian cancer in BRCA2 
was established at 11% versus 39% for BRCA1.17 A study on 
breast ovarian cancer families with at least two cases of ovarian 
cancer showed these families to be four times more likely to 
carry a BRCA1 mutation than a BRCA2 mutation.18 Likewise, 
in our study 9.6% of individuals in the BRCA1-positive group 
had ovarian cancer compared with 1.9% in the BRCA2-positive 
group (Table I), indicating a significant difference between the 
two groups (p<0.001). 
Male breast cancer
Our study supported our expectation that a BRCA2-mutation-
positive genotype would result in fewer ovarian cancer cases 
and more male breast cancer cases than in the BRCA1-positive 
group, as in other studies7,19 (Table I). Interestingly, in the 
BRCA-negative group the male breast cancer prevalence also 
appeared to be increased compared with what was expected 
for the general population (Table II). However, this may not 
be a true reflection as we selected families for the presence of 
male and female breast cancers. In the BRCA-negative group 
the 5 male cases each came from different families (1 case per 
family), whereas the 8 breast cancer cases observed in the 
BRCA2-positive group came from only 3 families (2.7 cases 
per family). It was reported previously that once an index case 
presents with male breast cancer in a BRCA2-positive family 
a number of other cases also emerge in the rest of the family.20 
This could possibly indicate gene-gene interactions that modify 
Table I. Family information, cancer cases and prevalence in 
the different study groups 
Groups      BRCA1+          BRCA2+       BRCA–
Families (N)           26   43         60
  With BC & OV          18   10           9
  With only BC             6   33         48
  With only OV            2     0           3
Females (N)         456                 719       834
Males (N)          337                 545        663
Unknown gender (N)          5   82          41
Cancer cases
(cases/family) (N)      219 (8.4)         375 (8.7)      342 (5.7)
Prevalence (%)
   Female BC (bil. BC)   24.6 (3.94)       31.0 (3.89)     25.1 (2.52)
   Diag. >50 yrs        18.1                28.7       33.0
   Diag. ≤50 yrs        69.1                55.4       57.4
   OV            9.6                  1.9        2.2
   Male BC          0.3                  1.5        0.8
   Cancers other than
   BC and OV           7.8                  9.7        7.2
   All cancers        27.4                27.9       22.2
BC = breast cancer; OV = ovarian cancer; Prevalence = N of cancer cases/N of 
individuals (female and/or male depending on the cancer type) × 100; bil. BC = 
bilateral breast cancer; Diag. = age at breast cancer diagnosis.
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penetrance of male breast cancer in certain BRCA2-positive 
families.
Other cancers
Of the other cancers recorded in the families, only stomach 
cancer in the BRCA2-positive group showed a significantly 
increased prevalence compared with the general population 
(Table II). 
Prostate, colon, bladder and lung cancers and melanoma 
appear to have a lower than expected prevalence in all three 
groups, probably because of incomplete reports of all cancers 
in the families. Some of these cancers have a high population 
risk, e.g. prostate cancer with a 1 in 14 lifetime risk. Incomplete 
reporting will affect the cancers with a higher population risk 
to a greater extent than those with a lower risk. To illustrate 
the point: if 30% of all cancers in a group of 1 346 individuals 
(similar in size to the BRCA2-positive group) were not 
reported, it would lead to 11 cases of unreported colon cancer 
(risk 1/35.5) while only 1 case of brain cancer (risk 1/339.5) 
would not be reported. 
Another consideration could be that the under-reported 
cases are not the same over all the cancer categories but that 
there are preferential reports on breast and ovarian cancer, as 
this study focused on these cancers. The clinic that collected the 
families for this study tried to limit this tendency by informing 
patients of the importance of recording all cancers before 
gathering their pedigree information. However, a bias may 
still remain and will persist in studies that rely on secondary 
information supplied by the family rather than on hospital and 
pathology records.
Table III presents reports13 that showed associations with 
various types of cancers compared with our study. As many 
of the cancers in our study had few reported cases, one must 
be careful to attach significance to the difference in prevalence 
between the groups. However, stomach and prostate cancer 
each had 40 or more reported cases. Stomach cancer had a 
significantly (p=0.0001) elevated prevalence in the BRCA2 
families compared with the general population and had twice 
the prevalence compared with the BRCA1-positive group. 
Although prostate cancer was not significantly elevated in the 
BRCA-mutation-positive groups compared with the general 
population, it is still interesting that the BRCA2-positive group 
had a 5 times higher prevalence compared with the BRCA1-
positive group (Table III). 
The BRCA-negative group
Just what the families that constitute the BRCA-negative 
group signify is uncertain. They may represent a diverse 
group of families with the hypothetical BRCA3 gene, families 
with genes of lower penetrance, families with mutations in 
high-penetrance genes that are very rare, or just families 
with BRCA1 or 2 mutations that were missed by the methods 
employed. Our methods are supposed to have a 71 - 79% 
sensitivity,21 giving an estimate of 27 - 37 families in the BRCA-
Table II. Comparison of observed cancer prevalence in the study groups with the expected prevalence 
                    BRCA1+                                   BRCA2+                                   BRCA–
Cancer          Observed Expected        Observed Expected         Observed Expected
type    Pop. risk          cases  cases    p-value          cases  cases    p-value           cases   cases    p-value
Breast          13              112  35.08  <0.00001             223   55.31  <0.00001              209   64.15   <0.00001
Male breast     476                 1    0.71        0.728                8    1.14  <0.00001                 5     1.39      0.0022
Ovarian        120               44    3.80  <0.00001              14    5.99        0.001                18     6.95    0.00003
Prostate          14                 3  24.07    0.00001              25   38.93      0.0205                12   47.36  <0.00001
Colon       35.5                 4  22.48    0.00008                5   37.92  <0.00001                 8   43.32  <0.00001
Stomach     120.5                 7    6.62      0.8829              24   11.17      0.0001               17   12.76      0.2337
Liver     264.5                 1    3.02      0.2446                8    5.09       0.196                 6     5.81      0.9388
Brain     339.5                 1    2.35       0.377                2    3.96      0.3231                 6     4.53      0.4892
Melanoma     50.5                 3  15.80      0.0011                3   26.65  <0.00001                 5   30.46  <0.00001
Pancreas        512                 2    1.56      0.7234                4    2.63      0.3973                 3     3.00      0.9975
Bladder       75.5                 0  10.57      0.0011                3   17.83      0.0004                 4   20.37      0.0003
Kidney        357                 2    2.24      0.8749                1    3.77      0.1531                 2     4.31      0.2655
Lung       47.5                 4    16.8      0.0016                8   28.34      0.0001                 9   32.38    0.00003
Thyroid        348                 1    2.29      0.3929                0    3.87      0.0489                 3     4.42        0.499
Throat     290.5                 1    2.75        0.291                4    4.63      0.7682                 5     5.29      0.8981
Uterus        108                 1    4.22      0.1152              10    6.66      0.1931                 1     7.72      0.0151
Cervix          93                 3    4.90      0.3875                4    7.73      0.1773                 0     8.97      0.0026
Other cancers               16                15                 20
Unspecified cancers               13                14                   9
Total cases       6.5             219           122.7692  <0.00001             375 207.08  <0.00001              342 236.62  <0.00001
Pop. risk = given as N, where N is the Caucasian population risk 1/N (Sitas et al., 19981); Observed cases = the number of cancer cases counted from pedigrees in each of the three groups 
(BRCA1-positive, BRCA2-positive and BRCA-negative families); Expected cases = expected cancer cases in the families calculated through multiplying the Caucasian population risk by the 
total number of individuals in each of the three groups; p-value = the probability that the observed number of cancer cases is in accordance with expected number of cancer cases in general 
Caucasian population; bold font = higher prevalence than general Caucasian population; italics = lower prevalence than general Caucasian population.
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negative group, which might have BRCA1/2 mutations that 
were missed by the current screening methods. However 
this still leaves 23 - 33 families in which the breast cancer 
phenotype can be ascribed to either rare high-penetrant genes 
or low-penetrant genes that might segregate in these families 
together with polymorphisms in other genes that enhance 
cancer penetrance. 
Conclusion
BRCA2 has been implicated in increased susceptibility to 
a larger range of cancers than BRCA1. This was also seen 
in our study, where the prevalence of breast, ovarian, male 
breast and stomach cancer was significantly increased in the 
BRCA2-positive group. Although cancers of the liver, prostate 
and uterus were more prevalent in the BRCA2-positive group 
than the other two groups, this was not significantly elevated 
compared with the general population.
Both BRCA1 and BRCA2 genes play an important role in the 
aetiology of familial breast cancer in South Africa. Reports have 
suggested mutation-specific cancer prevalence for 
the classically BRCA-associated cancers and other 
cancers.13 We report on the cancer risk profile in 
BRCA-mutation-positive and negative Caucasian 
breast-ovarian cancer families collected in South 
Africa. Our results regarding cancer risks in BRCA-
mutation-positive families largely agree with 
published data. This allows for more comprehensive 
counselling of Caucasian mutation-positive breast 
and breast-ovarian cancer families regarding 
their risks of breast-ovarian cancer and of other 
associated cancers.
We thank the families for their participation in the 
study, Marlene de la Rey for the DNA extractions, and 
the Cancer Association of South Africa (CANSA) for 
financial support to EJvR.
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Table III. Comparison with other studies showing association of BRCA genes with 
cancers other than breast and ovarian
                           Current study
Cancer type            BRCA1*          BRCA2*               BRCA1       BRCA2
Stomach     3            2    No       Significantly elevated
      association    prevalence compared to
            the general population 2
            times higher prevalence
            than BRCA1 families
            (not significant, p=0.069)
Prostate      2            5   No       No association
      association    5 times higher
            prevalence than BRCA1
            families
            (significant, p=0.0004)
Liver     1            -   No       No association
      association    5 times higher prevalence
            than BRCA1 families
Uterine corpus    1            -   No       No association
      association    6 times higher prevalence
            than BRCA1 families
Uterine cervix    1            1   No       No association
      association    Less than 1.5 times
            difference between groups
Melanoma    -            1   No       No association
     association     Less than 1.5 times
            difference between groups
Colon      3            2   No       No association
     association     Less than 1.5 times
            difference between groups
Pancreas     4            2   No       No association
     association     Less than 1.5 times
            difference between groups
*Number of studies that found a positive association with the gene. Information from Friedenson (2005).18
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